Answers are grounded in this paper and cite their sources.
Skin disorders such as chronic wounds, inflammation, and premature aging remain difficult to treat due to limited therapies and poor regeneration. Extracellular vesicles (EVs) are emerging as promising cell-free therapeutics, but those from human placenta or stem cells face ethical, cost, and scalability barriers. Here, we isolated and characterized sheep placenta-derived EVs (spEVs), an ethical and sustainable alternative. SpEVs exhibited a bilayer structure (150 nm) and expressed typical exosomal markers. Their RNA and protein cargos were enriched in regenerative and anti-inflammatory pathways. Functionally, spEVs promoted keratinocyte proliferation, migration, and angiogenesis, and improved psoriasis-like, UVB-induced, and diabetic wounds in mice. This study identifies sheep placenta as a scalable and ethical source of EVs with promising preclinical potential for skin regeneration.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: